Anglo French Drugs and Industries Unlisted Share Price
Anglo French Drugs and Industries unlisted share price is ₹1,075 per share (indicative, as of 18 Oct 2026). Minimum ticket ₹25,000 (lot of 24 shares), the same for every company. Sector: Consumer. Status: unlisted, no DRHP on record.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 18 Oct 2026, 14:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; Anglo French Drugs and Industries’s indicative price is ₹1,075 per share as of 18 Oct 2026, a lot of 24 shares.
Key facts
- Indicative price
- ₹1,075 per share
- Price as of
- 18 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 24 shares
- Sector
- Consumer
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 18 Oct 2026, 14:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 18 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE570E01016: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- Unlisted. No DRHP on record.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative quote unchanged since 25 Jun 2026 (115 dated quotes); no price movement to chart yet.
Key figures
| Market cap | ₹115.26 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 24 |
| P/E ratio | 17.34x |
| ROE | 6.39% |
| Book value | ₹1,195.84 |
| Face value | ₹10 |
| 52-week high | ₹1,075 |
| 52-week low | ₹1,075 |
| ISIN | INE570E01016 |
| Dividend yield | — |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | 95.2 | 87.8 |
| PAT | — | -12.3 | 7.22 |
| EPS (₹) | — | -99.0 | 62.0 |
About the company
Anglo-French Drugs & Industries Limited (AFDIL) is one of India's oldest pharmaceutical companies, with origins dating back to its incorporation in 1923. Headquartered in Bengaluru, Karnataka, the company has built a century-long presence in the Indian formulations market, developing and manufacturing a broad portfolio of nutraceutical and therapeutic products.
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Bengaluru, Karnataka.
Registry
- ISIN: INE570E01016
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 18 Oct 2026
Company facts
| CIN | L24230KA1923PLC010205 |
|---|---|
| Incorporated | 1923 |
| ISIN | INE570E01016 |
| Face value | ₹10 |
| Registered office | Plot No. 4, Phase II, Peenya Industrial Area, Peenya, Bengaluru 560058, Karnataka, India |
| Shares outstanding | 1,12,68,82,12,910 |
| Lot size | 24 shares |
| Minimum units | 10 |
| DRHP | Not filed |
Financial statements (₹ Cr)
| Metric | FY23 | FY24 | FY25 | FY25 vs FY24 |
|---|---|---|---|---|
| Revenue | 103 | 95.2 | 87.79 | −7.8% |
| EBITDA | −40.5 | −11 | −16.5 | −50% |
| Profit before tax | 251 | −12 | 8 | loss to profit |
| Profit after tax | 191 | −12.34 | 7.22 | loss to profit |
| EPS (₹) | 1,480.62 | −99 | 62 | loss to profit |
| Net margin | — | −13% | 6% | +19 pts |
| Share capital | — | 1.23 | 1.13 | −8.1% |
| Reserves & surplus | — | 169.67 | 123.67 | −27.1% |
| Net worth | — | 170.9 | 124.8 | −27% |
| Fixed assets | — | 15.41 | 22.19 | +44% |
| Investments | — | 125.19 | 95.52 | −23.7% |
| Trade receivables | — | 41.81 | 32.1 | −23.2% |
| Trade payables | — | 20.7 | 28.47 | +37.5% |
| Cash from operations | — | 3 | 1.91 | −36.3% |
| Cash from investing | — | 41.36 | 44.71 | +8.1% |
| Cash from financing | — | −47.11 | −46.49 | +1.3% |
| Net cash generated | — | −2.75 | 0.13 | loss to profit |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹1,075 | dealer reference, 18 Oct 2026 |
| Market cap | ₹115.26 Cr | as recorded |
| P/E | 17.34x | price ÷ EPS ₹62 (FY25) |
| P/B | 0.9x | price ÷ book value ₹1,195.84 |
| EPS | ₹62 | per share, FY25 |
| Book value | ₹1,195.84 | per share, latest books |
| RoE | 6.39% | return on equity, latest FY |
| Debt / equity | 0.15 | latest balance sheet |
| Dividend yield | — | |
| Face value | ₹10 | per share |
| 52-week range | ₹1,075 (unchanged) | quote unchanged since 25 Jun 2026 |
| Shares outstanding | — | not meaningful |
Shareholding pattern
| Category | Holder | % of equity |
|---|---|---|
| Promoters | Promoter & Promoter Group | 64.83% |
| Public | Public | 35.17% |
Promoters 64.83% · Public 35.17%
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Abhay Kanoria | Chairman & Managing Director | — |
| Uddhav Kanoria | President & Whole-time Director | — |
| Nirbhay Kanoria | Whole-time Director | — |
| Sanatkumar Manjunath Shirali | Independent Director | — |
| Nalagath Ahmedali | Independent Director | — |
| Neha Gada | Independent Director | — |
| Shashikant N More | Nominee Director | — |
| Rajeshwar B Smarta | Additional Independent Director | — |
| Rakesh P Kanyadi | Additional Non-Executive Director | — |
Business model
Anglo-French Drugs & Industries manufactures and markets pharmaceutical formulations, while also buying and selling pharmaceutical products as part of its healthcare operations. Its annual report identifies formulations across therapeutic groups including vitamins, sleep-inducing agents, anti-malarials, anti-epileptics, antibiotics, cardiac drugs, cold remedies, anti-ulcer products, hematinics, antifungals and oral hypoglycaemics. The company runs tablet, liquid, capsule and protein-preparation capabilities and carries out contract manufacturing for other companies.
Its business is organised around divisions such as Optima, which sells medicines through Indian channels, and Hospicare, which serves orthopaedic and general-health needs through institutional and surgical channels. Revenue from operations in the audited statements is mainly product sales, with smaller operating revenue from scrap, job-work conversion charges and miscellaneous operating income. It also exports pharmaceutical products, with the report describing operations in multiple overseas markets.
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Undated | Other | The Board approved shifting the registered office from Bengaluru to Mumbai. (02 May 2025) | — | Source |
| Undated | Other | Abhay Kanoria was re-designated as Chairman, and Uddhav Abhay Kanoria and Nirbhay Abhay Kanoria were re-designated as Managing Directors. (20 Mar 2025) | — | Source |
| Undated | Other | Manik Kumar Singh was appointed Chief Financial Officer. (29 Jul 2024) | — | Source |
| Undated | Other | Rani Shokeen was appointed as an Additional Director by the Board. (28 May 2024) | — | Source |
Reports and filings
No filings uploaded yet.
Annual reports
Frequently asked questions
What does Anglo-French Drugs & Industries Limited do?
Anglo-French Drugs & Industries Limited (AFDIL) is a Bengaluru-based pharmaceutical company incorporated in 1923. It manufactures and markets nutraceutical and therapeutic formulations, including vitamins, protein and food supplements, anti-epileptics, anti-oxidants, sleep-inducing agents, cold and cough preparations, digestive enzymes, calcium supplements, antibiotics, cardiac and anti-inflammatory drugs. It operates through divisions such as AFD Pharma, Hospicare and Optima, and serves both domestic and export markets.
Is Anglo-French Drugs & Industries listed, and how can its unlisted shares be bought or sold?
The company is not listed on the NSE or BSE main board. Its shares were historically admitted on the Metropolitan Stock Exchange of India but have not traded there in recent years, so they effectively transact as unlisted shares in the off-market. Transfers happen demat-to-demat through NSDL/CDSL depository participants.
What determines the indicative price of Anglo-French Drugs unlisted shares?
As an unlisted, off-market security, its indicative price is set by buyer and seller negotiation rather than by a continuous exchange order book. The quoted figure reflects current demand and supply, available free float, the company's reported financials and book value, broader sentiment toward unlisted pharmaceutical names, and any recent corporate disclosures. Because liquidity is limited, the indicative price can move and may differ across sources and dates.
What are the key fundamentals of Anglo-French Drugs & Industries?
Key reference details include ISIN INE570E01016, CIN L24230KA1923PLC010205, a face value of ₹10 per share, incorporation in 1923, and a registered office in Bengaluru, Karnataka. The company is associated with the Kanoria promoter family and reported revenue of around ₹118 crore for the financial year ending March 2025. These figures are factual reference data and indicative market information, not investment advice.
What is the Anglo French Drugs and Industries unlisted share price today?
The indicative over-the-counter reference price is ₹1,075 per share as of 18 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is Anglo French Drugs and Industries listed on a stock exchange?
Not yet. Anglo French Drugs and Industries changes hands in the unlisted market, over the counter and settle into your demat account through NSDL and CDSL.
What is the minimum investment in Anglo French Drugs and Industries?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of Anglo French Drugs and Industries?
INE570E01016. Holdings are settled in demat form through NSDL and CDSL.
How do I buy Anglo French Drugs and Industries unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if Anglo French Drugs and Industries lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- Anglo French Drugs and Industries annual report 2023-24 · FY 2023-24 · msei.in
- Other: The Board approved shifting the registered office from Bengaluru to Mumbai. (02 May 2025) · msei.in
- BuyUnlistedShares indicative price series for Anglo French Drugs and Industries, dated daily · since 25 Jun 2026 (115 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Anglo French Drugs and Industries unlisted share price”, https://buyunlistedshares.com/unlisted-shares/anglo-french-drugs-and-industries, as of 18 Oct 2026.
Other Consumer unlisted shares
- A V Thomas & Co. Limited · ₹12,500
- Anheuser Busch Inbev India (AB InBev) · ₹555
- Apollo Fashion International · ₹44
- Arch Pharmalabs Limited · ₹85
- Auckland Jute Co. Limited · ₹189
- Axles India Limited · ₹625
Enquire to buy Anglo French Drugs and Industries · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 18 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
